13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002050709
Total reported value
$322.2M
$322.2M
33 檔
44.8%
At the close of Q1 2026, Squadron Capital Management LLC disclosed equity holdings valued at approximately $322.2M, spread across 33 reported holdings.
Squadron Capital Management LLC executed strategic sector rebalancing during Q1 2026, establishing 15 new positions while fully exiting 15 holdings and trimming 8 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RLMD | Relmada Therapeutics Inc | Stock-Other | 21.61% | -5.83% | +26.49% | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 11.11% | -0.72% | +0.96% | |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 9.59% | -9.59% | EXIT | |
| 4 | KOD | Kodiak Sciences Inc | Stock-Other | 5.31% | +0.74% | +30.27% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 5.30% | -5.30% | EXIT | |
| 6 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.04% | -0.38% | — | |
| 7 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 3.46% | +2.75% | — | |
| 8 | NKTR | Nektar Therapeutics | Stock-Other | 3.30% | -3.30% | EXIT | |
| 9 | ANL | Adlai Nortye Ltd-adr | Stock-Other | 3.21% | -0.48% | — | |
| 10 | RLAY | Relay Therapeutics Inc | Stock-Other | 3.00% | +2.63% | — | |
| 11 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.82% | +0.28% | -47.45% | |
| 12 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.74% | -2.74% | EXIT | |
| 13 | SCYXEUR | Scynexis Inc | Stock-Other | 2.56% | -2.56% | EXIT | |
| 14 | CCCC | C4 Therapeutics Inc | Stock-Other | 2.17% | +8.84% | — | |
| 15 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 2.15% | -0.26% | -17.16% | |
| 16 | PALI | Palisade Bio Inc | Stock-Other | 1.92% | +0.03% | -33.33% | |
| 17 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 1.80% | -1.80% | EXIT | |
| 18 | GHRS | GH Research PLC | Stock-Other | 1.67% | -1.67% | EXIT | |
| 19 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 1.53% | -1.53% | EXIT | |
| 20 | PMN | Promis Neurosciences Inc | Stock-Other | 1.51% | -0.18% | — | |
| 21 | LPCN | Lipocine Inc | Stock-Other | 1.32% | -0.68% | -15.09% | |
| 22 | IVA | Inventiva SA - Adr | Stock-Other | 1.09% | +1.77% | +78.33% | |
| 23 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 1.07% | -1.07% | EXIT | |
| 24 | CNTX | Context Therapeutics Inc | Stock-Other | 1.06% | -1.06% | EXIT | |
| 25 | NXTC | Nextcure Inc | Stock-Other | 1.04% | -1.01% | +11.83% | |
| 26 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.93% | +1.04% | -67.46% | |
| 27 | ✓ | Stock-Other | 0.90% | +0.30% | — | ||
| 28 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.57% | -0.41% | — | |
| 29 | TRAW | Traws Pharma Inc | Stock-Other | 0.34% | -0.34% | EXIT | |
| 30 | TXMD | Therapeuticsmd Inc | Stock-Other | 0.31% | -0.31% | EXIT | |
| 31 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.29% | -0.29% | EXIT | |
| 32 | HOWL | Werewolf Therapeutics Inc | Stock-Other | 0.17% | -0.17% | EXIT | |
| 33 | NEUP | Neuphoria Therapeutics Inc | Stock-Other | 0.11% | -0.11% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RLMD | Relmada Therapeutics Inc | +7.9% | +26.49% | Add |
| 2 | 4XC1 | Kalvista Pharmaceuticals Inc | +4.8% | +85.73% | Add |
| 3 | KOD | Kodiak Sciences Inc | +1.9% | +30.27% | Add |
| 4 | IVA | Inventiva SA - Adr | +0.5% | +78.33% | Add |
| 5 | EWTX | Edgewise Therapeutics Inc | +0.4% | — | Unchanged |
| 6 | EPRX | Eupraxia Pharmaceuticals Inc | +0.2% | +36.00% | Add |
| 7 | TRAW | Traws Pharma Inc | — | -28.29% | Trim |
| 8 | GHRS | GH Research PLC | 0% | +3.17% | Add |
| 9 | NXTC | Nextcure Inc | -0.4% | +11.83% | Add |
| 10 | LPCN | Lipocine Inc | -0.5% | -15.09% | Trim |
| 11 | KTTA | Pasithea Therapeutics CORP | -0.6% | — | Unchanged |
| 12 | COGT | Cogent Biosciences Inc | -0.6% | +0.96% | Add |
| 13 | IKT | Inhibikase Therapeutics Inc | -1.5% | -17.16% | Trim |
| 14 | AVBP | Arrivent Biopharma Inc | -2% | -67.46% | Trim |
| 15 | SPRB | Spruce Biosciences Inc | -2.3% | -82.57% | Trim |
| 16 | PALI | Palisade Bio Inc | -2.6% | -33.33% | Trim |
| 17 | ABVX | Abivax Sa-adr | -3% | -10.34% | Trim |
| 18 | MAZE | Maze Therapeutics Inc | -5.8% | -47.45% | Trim |
| 19 | ZNTL | Zentalis Pharmaceuticals Inc | — | NEW | New buy |
| 20 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 21 | ANL | Adlai Nortye Ltd-adr | — | NEW | New buy |
| 22 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 23 | 430 | Terns Pharmaceuticals Inc | — | EXIT | Sold out |
| 24 | IDYA | Ideaya Biosciences Inc | — | NEW | New buy |
| 25 | SCYXEUR | Scynexis Inc | — | NEW | New buy |
| 26 | TARS | Tarsus Pharmaceuticals Inc | — | EXIT | Sold out |
| 27 | UPB | Upstream Bio Inc | — | EXIT | Sold out |
| 28 | CCCC | C4 Therapeutics Inc | — | NEW | New buy |
| 29 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | DBVT | Dbv Technologies Sa-spon Adr | — | EXIT | Sold out |
| 31 | HELP | Cybin Inc | — | EXIT | Sold out |
| 32 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
| 33 | BLTE | Belite Bio Inc - Adr | — | EXIT | Sold out |
| 34 | PMN | Promis Neurosciences Inc | — | NEW | New buy |
| 35 | VTYXUSD | Ventyx Biosciences Inc | — | EXIT | Sold out |
| 36 | VERA | Vera Therapeutics Inc | — | EXIT | Sold out |
| 37 | WVE | Wave Life Sciences Ltd. | — | EXIT | Sold out |
| 38 | ALXO | Alx Oncology Holdings Inc | — | NEW | New buy |
| 39 | CNTX | Context Therapeutics Inc | — | NEW | New buy |
| 40 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
| 41 | ✓ | — | NEW | New buy | |
| 42 | AVTX | Avalo Therapeutics Inc | — | EXIT | Sold out |
| 43 | ZBIO | Zenas Biopharma Inc | — | EXIT | Sold out |
| 44 | TXMD | Therapeuticsmd Inc | — | NEW | New buy |
| 45 | NTLA | Intellia Therapeutics Inc | — | EXIT | Sold out |
| 46 | HOWL | Werewolf Therapeutics Inc | — | NEW | New buy |
| 47 | CLYM | Climb Bio Inc | — | EXIT | Sold out |
| 48 | NEUP | Neuphoria Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Squadron Capital Management LLC reported a total U.S. public equity portfolio value of $322.2M across 33 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RLMD, COGT, 4XC1) accounted for 44.8% of total reported equity market value during Q1 2026.
Top New Position Initiated
ZNTL
市值: $9.4M
Top Position Liquidated / Trimmed
430
前期市值: $7.7M
During Q1 2026, Squadron Capital Management LLC's top holdings by market value included RLMD (21.6%)、COGT (11.1%)、4XC1 (9.6%). The largest single position, RLMD, represented 21.6% of total portfolio value.
In Q1 2026, Squadron Capital Management LLC made 46 total portfolio adjustments, initiating 15 new buys, adding to 8 positions, trimming 8 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.